Rivastigmine in Mild Alzheimer's Disease, FMRI Study

Not Applicable

Completed

• Conditions: Alzheimer' Disease

• Registration Number: NCT00627848
• Lead Sponsor: Kuopio University Hospital

Brief Summary

The purpose of the study is to investigate the effect of rivastigmine given as an acute dose compared to placebo and after 1 month chronic dosing on fMRI response during a face recognition task. Furthermore, the aim is to investigate whether fMRI response is correlated with long term treatment effect at 6 months and 12 months.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-03
• Study First Submitted: 2008-02-22
• Study First Submitted QC: 2008-02-22
• Study First Posted: 2008-03-03
• Primary Completion: 2008-12
• Study Completion: 2008-12
• Status Verified: 2011-10
• Last Update Submitted: 2011-10-27
• Last Update Posted: 2011-10-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Probable Alzheimer's disease according to the NINCDS-ADRDA criteria
• mild disease, CDR 1
• the clinician is planning to start anticholinesterase treatment

Exclusion Criteria

• cognitive impairment for other reason than Alzheimer's disease
• severe depression
• other unstable physical disease
• medal in body prevention MRI examination, claustrophobia
• cardiac pacemaker
• other significant neurologic or psychiatric disease
• contraindication for anticholinesterase treatment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
FMRI response in face recognition task	at baseline and at 1 mo

Secondary Outcome Measures

Name	Time	Method
treatment response measured by ADAS-cog	at 6 month and 1 year

Trial Locations

Locations (1)

Kuopio University Hospital; 🇫🇮 Kuopio, Finland